Table - PMC

Skip to main content

View full-text article in PMC

. 2015 Dec 28;12:S1–S110. doi: 10.1111/j.1470-9465.2006.12_4_1426.x

	Study 1 Antifungal Prophylaxis in HSCTRecipients With GVHD			Study 2 Antifungal Prophylaxis in AML or MD3 Patients With Neutropenia
Incidence, n (%)	POS (n=301)	FLU (n=299)	P value	POS (n=304)	FLU or ITZ (n=298)	P value
Proven/probable infections while on treatment

All IFIs	7 (2)^a	22 (8)^b	.0038	7 (2)	25 (8)	.0009

Invasive aspergillosis	3 (1)^a	17 (6)^b	.0009	2 (1)	20 (7)	.0001

Proven/probable infections during fixed time period^c

All IFIs	16 (5)	27 (9)	.0740	14 (5)	33 (11)	.0051

Invasive aspergillosis	7 (2)	21 (7)	.0059	4 (1)	20 (9)	.0001

^a.

n=291 (treated subjects)

^b.

n=288 (treated subjects)

^c.

Within 112 days postbaseline in study 1; within 100 days postrandomisation in study 2.